Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

The Strong Prognostic Effect of Concurrent Deletions of IKZF1 and PAX5 , CDKN2A , CDKN2B or PAR1 in the Absence of ERG Deletions (IKZF1 plus ) in Pediatric Acute Lymphoblastic Leukemia Strongly Depends on Minimal Residual Disease Burden after Induction Treatment

Blood (2014) 124 (21): 131.

https://doi.org/10.1182/blood.V124.21.131.131

Published: 2014

Journal Articles

Gain of 1q21 Is a Cytogenetic Independent Risk Factor in Light Chain Amyloidosis Patients Treated with Melphalan / Dexamethasone As First-Line Therapy,

Tilmann Bochtler, MD, Ute Hegenbart, MD, Axel Benner, Dirk Hose, MD, Anja Seckinger, Kai Neben, MD, Sascha Dietrich, MD, Claus R Bartram, MD, Anthony D. Ho, MD, Hartmut Goldschmidt, MD, Anna Jauch, PhD, Stefan O Schonland, MD

Blood (2011) 118 (21): 3946.

https://doi.org/10.1182/blood.V118.21.3946.3946

Published: 2011

Journal Articles

Repeated Bone Marrow Aspiration At the End of Induction Therapy: Implications for Treatment Stratification in Paediatric Acute Lymphoblastic Leukaemia

Jan Zuna, MD, PhD, Mari Arens, Rolf Koehler, PhD, Renate Panzer-Grümayer, MD, Anja Möricke, MD, Claus R Bartram, MD, Ruth Joas, Eva Fronkova, Gunnar Cario, MD, Martin Stanulla, MD, MSc, Martin Zimmermann, PhD, Jan Trka, MD, PhD, Jan Stary, M.D., Andishe Attarbaschi, MD, Georg Mann, MD, Martin Schrappe, MD, André Schrauder, MD

Blood (2011) 118 (21): 756.

https://doi.org/10.1182/blood.V118.21.756.756

Published: 2011

Journal Articles

Major Improvement of Outcome in Pediatric High-Risk Acute Lymphoblastic Leukemia by Addition of BFM Chemotherapy Element “Phase IB”: A Comparative Data Analysis of Trials ALL-BFM 95 and ALL-BFM 2000

Anja Möricke, MD, André Schrauder, MD, Martin Zimmermann, PhD, Georg Mann, MD, Andishe Attarbaschi, MD, Rolf Koehler, PhD, Renate Panzer-Grümayer, MD, Martin Stanulla, MD, MSc, Gunnar Cario, MD, Alfred Reiter, MD, Felix Niggli, MD, Claus R Bartram, MD, Martin Schrappe, MD

Blood (2011) 118 (21): 1504.

https://doi.org/10.1182/blood.V118.21.1504.1504

Published: 2011

Journal Articles

IKZF1 Deletion Is An Independent Predictor of Outcome In Pediatric Acute Lymphoblastic Leukemia Treated According to the ALL-BFM 2000 Protocol

Petra Breithaupt, PhD, Barbara Meissner, MD, Martin Zimmermann, Anja Möricke, MD, André Schrauder, MD, Jochen Harbott, Wolf-Dieter Ludwig, MD, PhD, Rolf Köhler, PhD, Claus R Bartram, MD, Martin Schrappe, MD, Gunnar Cario, MD, Martin Stanulla, MD, MSc

Blood (2010) 116 (21): 409.

https://doi.org/10.1182/blood.V116.21.409.409

Published: 2010

Journal Articles

Hyperdiploidy Is Rare in Patients with AL Amyloidosis – Identification of Major Cytogenetic Groups in Early Monoclonal Plasma Cell Disorders.

Tilmann Bochtler, Ute Hegenbart, MD, Christiane Heiss, Axel Benner, Stephanie Pschowski-Zuck, Désirée Kirn, Kai Neben, Marion Moos, D. Hose, Claus R Bartram, MD, Anthony D. Ho, MD, PhD, Hartmut Goldschmidt, Anna Jauch, Stefan Schonland

Blood (2009) 114 (22): 2823.

https://doi.org/10.1182/blood.V114.22.2823.2823

Published: 2009

Journal Articles

Dexamethasone in Induction Can Eliminate One Third of All Relapses in Childhood Acute Lymphoblastic Leukemia (ALL): Results of An International Randomized Trial in 3655 Patients (Trial AIEOP-BFM ALL 2000)

Martin Schrappe, MD, Martin Zimmermann, PhD, Anja Möricke, MD, Georg Mann, MD, Maria Grazia Valsecchi, PhD, Claus R Bartram, MD, Andrea Biondi, MD, Renate Panzer-Grümayer, MD, André Schrauder, MD, Franco Locatelli, MD, Alfred Reiter, MD, Giuseppe Basso, MD, Felix Niggli, MD, Maurizio Aricò, MD, Valentino Conter, MD

Blood (2008) 112 (11): 7.

https://doi.org/10.1182/blood.V112.11.7.7

Published: 2008

Journal Articles

Prognostic Impact of Minimal Residual Disease (MRD) in Children Is Different in B or T Lineage Acute Lymphoblastic Leukemia: Results of Trial AIEOP-BFM ALL 2000.

Blood (2007) 110 (11): 1425.

https://doi.org/10.1182/blood.V110.11.1425.1425

Published: 2007

Journal Articles

Evaluation of the Cytogenetic Aberration Pattern in AL Amyloidosis Compared to Monoclonal Gammopathies Not Requiring Treatment: Translocation t(11;14) Is More Frequent in AL Amyloidosis.

Tilmann Bochtler, MD, Stefan O. Schonland, MD, Anna Jauch, PhD, Christiane Heiss, Axel Benner, PhD, Friedrich W. Cremer, MD, Dirk Hose, Marion Moos, PhD, Claus R. Bartram, MD, Anthony D. Ho, MD, Hartmut Goldschmidt, MD, Ute Hegenbart, MD

Blood (2007) 110 (11): 2500.

https://doi.org/10.1182/blood.V110.11.2500.2500

Published: 2007

Journal Articles

Prospective Evaluation of MRD-Kinetics in 274 Children with High-Risk ALL Treated in Trial ALL-BFM 2000: Insights into Development of Resistance and Impact on Further Refinement of Treatment Stratification Strategies.

André Schrauder, MD, Martin Stanulla, MD, Thomas Flohr, PhD, Gunnar Cario, MD, Rolf Köhler, PhD, Renate Panzer-Grümayer, MD, Beat Schäfer, PhD, Martin Zimmermann, PhD, Christina Peters, MD, Claus R. Bartram, MD, Martin Schrappe, MD

Blood (2007) 110 (11): 585.

https://doi.org/10.1182/blood.V110.11.585.585

Published: 2007

Journal Articles

Methylation Status and Polymorphism of Asparagine Synthetase Gene in Acute Lymphoblastic Leukemia Cells.

Tadayuki Akagi, PhD, Dong Yin, PhD, Norihiko Kawamata, MD, Claus R. Bartram, MD, Carl W. Miller, Ph.D, Phillip H. Koeffler, MD

Blood (2005) 106 (11): 847.

https://doi.org/10.1182/blood.V106.11.847.847

Published: 2005

NARROW

The Strong Prognostic Effect of Concurrent Deletions of IKZF1 and PAX5 , CDKN2A , CDKN2B or PAR1 in the Absence of ERG Deletions (IKZF1 plus ) in Pediatric Acute Lymphoblastic Leukemia Strongly Depends on Minimal Residual Disease Burden after Induction Treatment

Gain of 1q21 Is a Cytogenetic Independent Risk Factor in Light Chain Amyloidosis Patients Treated with Melphalan / Dexamethasone As First-Line Therapy,

Repeated Bone Marrow Aspiration At the End of Induction Therapy: Implications for Treatment Stratification in Paediatric Acute Lymphoblastic Leukaemia

Major Improvement of Outcome in Pediatric High-Risk Acute Lymphoblastic Leukemia by Addition of BFM Chemotherapy Element “Phase IB”: A Comparative Data Analysis of Trials ALL-BFM 95 and ALL-BFM 2000

IKZF1 Deletion Is An Independent Predictor of Outcome In Pediatric Acute Lymphoblastic Leukemia Treated According to the ALL-BFM 2000 Protocol

Hyperdiploidy Is Rare in Patients with AL Amyloidosis – Identification of Major Cytogenetic Groups in Early Monoclonal Plasma Cell Disorders.

Dexamethasone in Induction Can Eliminate One Third of All Relapses in Childhood Acute Lymphoblastic Leukemia (ALL): Results of An International Randomized Trial in 3655 Patients (Trial AIEOP-BFM ALL 2000)

Prognostic Impact of Minimal Residual Disease (MRD) in Children Is Different in B or T Lineage Acute Lymphoblastic Leukemia: Results of Trial AIEOP-BFM ALL 2000.

Evaluation of the Cytogenetic Aberration Pattern in AL Amyloidosis Compared to Monoclonal Gammopathies Not Requiring Treatment: Translocation t(11;14) Is More Frequent in AL Amyloidosis.

Prospective Evaluation of MRD-Kinetics in 274 Children with High-Risk ALL Treated in Trial ALL-BFM 2000: Insights into Development of Resistance and Impact on Further Refinement of Treatment Stratification Strategies.

Methylation Status and Polymorphism of Asparagine Synthetase Gene in Acute Lymphoblastic Leukemia Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only